State of Alaska Department of Revenue Sells 155 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

State of Alaska Department of Revenue decreased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,927 shares of the medical equipment provider’s stock after selling 155 shares during the quarter. State of Alaska Department of Revenue’s holdings in Lantheus were worth $709,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also bought and sold shares of the business. Wilmington Savings Fund Society FSB bought a new stake in Lantheus in the third quarter worth $25,000. Signaturefd LLC lifted its position in shares of Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 92 shares during the last quarter. UMB Bank n.a. boosted its stake in shares of Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 134 shares during the period. World Investment Advisors LLC bought a new position in shares of Lantheus in the third quarter worth about $60,000. Finally, RiverPark Advisors LLC bought a new stake in Lantheus during the 3rd quarter valued at about $74,000. Institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

LNTH has been the topic of a number of recent research reports. JMP Securities reissued a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial reissued a “buy” rating and set a $120.00 price target (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, The Goldman Sachs Group started coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $131.86.

Insider Buying and Selling at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.50% of the company’s stock.

Lantheus Trading Down 2.5 %

Lantheus stock opened at $79.94 on Friday. The company has a 50-day moving average price of $91.43 and a 200 day moving average price of $97.79. Lantheus Holdings, Inc. has a 12-month low of $56.06 and a 12-month high of $126.89. The stock has a market cap of $5.56 billion, a P/E ratio of 13.30 and a beta of 0.44.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.